OncoMatch

OncoMatch/Ovarian Cancer/BRCA2

Ovarian CancerBRCA2 Clinical Trials

18 recruiting trials·Updated daily from ClinicalTrials.gov

Germline and somatic BRCA2 pathogenic variants occur in approximately 10–15% of high-grade serous ovarian carcinoma. BRCA2-mutant tumors are highly sensitive to platinum chemotherapy and PARP inhibitors; BRCA2 somatic reversion mutations are a key mechanism of acquired PARP inhibitor resistance. Active trials study PARP inhibitor maintenance, combination strategies targeting HRD pathway co-vulnerabilities, and approaches to overcome or prevent PARP inhibitor resistance.

Match trials to my profileClinician mode →
Top recruiting

Top recruiting BRCA2 Ovarian Cancer trials

Ranked by phase and US site count.

See all trials matched to your profile →
Phase 3674 US sites

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

NRG Oncology

Phase 22 US sites

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Roswell Park Cancer Institute

Phase 21 US site

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Alexander B Olawaiye, MD

Phase 21 US site

Autophagy Maintenance (AUTOMAIN)

Medical University of South Carolina

Phase 2

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

MedSIR

Phase 2

Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer

Qilu Hospital of Shandong University

Additional trials

More BRCA2 Ovarian Cancer trials

Phase 2
Phase 1
9 international trials (no US sites)
NCT05200260Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian CancerPhase 2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerPhase 2NCT05183984Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian CancerPhase 2NCT04834544A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of CarePhase 2NCT07069335A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian CancerPhase 1NCT07156253Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid TumorsPhase 1NCT06666270Study of SYN818 for the Treatment of Advanced or Metastatic Solid TumorsPhase 1NCT07371104Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian CancerPhase 1NCT07673861Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer PatientsNA
Other Ovarian Cancer biomarkers

Browse other molecular targets with active Ovarian Cancer trials.

BRCA1Folate Receptor Alpha (FRα)
← All Ovarian Cancer clinical trials